Article Text

Download PDFPDF
ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In emergency department (ED) patients with atrial fibrillation (AF) and a rapid ventricular response rate, what is the efficacy and safety of magnesium sulphate administered within the first 2.5 hours in addition to usual care?

Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Emergency medicine ★★★★★★☆ Cardiology ★★★★★★☆


Embedded ImageDesign:

randomised controlled trial (RCT).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (patients, clinicians, {data collectors, outcome assessors, monitoring committee}, and data analysts).*

Embedded ImageFollow up period:

up to 150 minutes.

Embedded ImageSetting:

2 academic, tertiary referral EDs in South Australia.

Embedded ImagePatients:

199 patients (approximately 52% women) >18 years of age who presented to the ED with AF and a ventricular response rate >120 beats/min. Exclusion criteria were haemodynamic instability, history of renal failure or atrioventricular node disease (except for patients with primary atrioventricular block or permanent pacemakers), or acute myocardial infarction with electrocardiographic …

View Full Text


  • * *See glossary.

  • Information provided by author.

  • For correspondence: Dr M J Davey, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

  • Source of funding: no external funding.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd